IRIDEX Corporation — Q1 2017 Form 10-Q
Reporting period: Three months ended April 1, 2017 (13 weeks); comparative period ended April 2, 2016 (also 13 weeks). IRIDEX develops and sells ophthalmic medical laser systems, delivery devices, consumables, and related services. Amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2017 | Q1 2016 / comparator |
|---|---|---|
| Revenue | $10.483 million | $11.931 million |
| Gross profit / margin | $4.465 million / 42.6% | $5.297 million / 44.4% |
| Operating expenses | $6.323 million | $5.145 million |
| Operating income (loss) | $(1.858) million | $0.152 million |
| Net income (loss) | $(1.866) million; $(0.16) per diluted share | $0.101 million; $0.01 per diluted share |
| Cash from operations | $(1.622) million | $0.526 million |
| Cash and cash equivalents | $23.858 million at April 1, 2017 | $23.747 million at December 31, 2016 |
| Working capital | $37.9 million | $37.4 million at December 31, 2016 |
Cash used in investing activities was $0.425 million, including $0.341 million for property and equipment and $0.084 million of earn-out payments. Financing activities provided $2.158 million, including $2.263 million of net proceeds from a common-stock issuance and $0.163 million from option exercises, partly offset by $0.268 million of taxes paid on equity awards. Cash increased by $0.111 million during the quarter.
At April 1, 2017, total assets were $47.428 million and total liabilities were $7.584 million. The balance sheet reports no interest-bearing debt; management also said it had no fixed- or variable-rate debt outstanding. The filing states existing cash should meet anticipated cash needs for the next 12 months. Contractual obligations totaled $10.046 million, including $7.934 million of purchase commitments and $2.112 million of operating lease payments.
Material changes versus prior period
- Revenue fell $1.448 million, or 12.1%. International system sales declined $1.574 million, or 34.6%, while domestic system sales declined 3.5%. Management attributed the system-sales weakness primarily to retina laser systems.
- Recurring revenue rose 3.9% to $5.377 million, driven by G6-related probes, partly offset by lower EndoProbe revenue.
- Gross margin declined 1.8 percentage points. Management cited lower overhead absorption and higher manufacturing variances, including inventory and warranty reserve adjustments; higher direct margins from product and geographic mix partly offset the decline.
- Research and development expense increased 10.1% to $1.496 million; sales and marketing expense rose 20.3% to $2.923 million; general and administrative expense increased 40.3% to $1.904 million. The company cited increased headcount and related costs, with stock compensation and professional costs also contributing to G&A growth.
- International sales were 45.6% of revenue, down from 51.0%. No customer represented more than 10% of Q1 2017 revenue; one customer represented 15% in Q1 2016.
Outlook, risks, contingencies, and unusual items
- Outlook: No specific revenue or earnings guidance is provided. Management expects cash on hand to cover anticipated needs over the next 12 months and cautions that gross margins may continue to fluctuate with sales mix, volume, manufacturing efficiency, and other factors.
- Warranty: Beginning in March 2017, IRIDEX offered a five-year warranty on laser heads for IQ 532/577 consoles, compared with its prior one-to-two-year product warranties. The accrued warranty liability was $0.649 million at quarter-end.
- Lease: A new headquarters lease signed April 26, 2017 extends occupancy through February 2022. It provides for approximately $100,000 monthly base rent beginning March 1, 2019, plus certain operating expenses and taxes; the landlord has a termination right subject to advance notice.
- Risks: Key exposures include volatile demand and quarterly results, dependence on international distributors and sales, production and quality-control challenges, sole- or limited-source suppliers, competition, product acceptance and development, reimbursement and regulatory changes, and healthcare-law compliance. International sales were denominated in U.S. dollars during the quarter, but a stronger U.S. dollar could make products less competitive abroad. The company does not currently hedge currency risk.
- Contingencies and accounting: The Level 3 earn-out liability was $0.634 million at April 1, 2017, based on projected royalties and discount-rate assumptions. Management said ordinary-course legal matters were not expected to have a material adverse effect. The company recorded a full valuation allowance against federal and state deferred tax assets. Adoption of inventory and share-based-payment accounting updates had no material financial statement impact.
- Controls: Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of April 1, 2017; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether the sharp decline in international system sales and retina laser demand continues, and whether recurring probe revenue can offset system weakness.
- Whether operating expenses and manufacturing costs can be aligned with revenue, given the quarterly operating loss, lower gross margin, and cash use from operations.
- The expected cost and reserve adequacy associated with the new five-year laser-head warranty.
- Assumptions behind the earn-out liability and the timing and cash impact of purchase commitments and lease obligations, including the new lease’s termination provision.
- That the filing provides no specific financial guidance; monitor actual performance against management’s 12-month liquidity statement and stated risks.